Aravive Interest Expense 2011-2026 | ARAV

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Aravive

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
2.84 M	1.46 M	-14 K	2.53 M	2.43 M	528 K	236 K	113 K	-11.5 M	128 K	393 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.84 M	-11.5 M	-80.1 K

Quarterly Interest Expense Aravive

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
700 K	650 K	697 K	-	738 K	705 K	703 K	-	479 K	295 K	-5 K	-	31 K	656 K	-701 K	-	624 K	597 K	689 K	-	-593 K	-656 K	-657 K	-547 K	-262 K	-521 K	-261 K	446 K	-39 K	59 K	-230 K	32 K	91 K	-236 K	226 K	244 K	208 K	-141 K	-11.8 M	44 K	128 K	128 K	128 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
738 K	-11.8 M	-195 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	722 K	-	-	$ 866 M	China
Apellis Pharmaceuticals APLS	-133 K	$ 20.22	-2.32 %	$ 2.55 B	USA
Axsome Therapeutics AXSM	-15.9 M	$ 164.71	-1.01 %	$ 8.19 B	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.73	-2.49 %	$ 1.11 B	Canada
Catalyst Pharmaceuticals CPRX	25.7 M	$ 23.88	-	$ 2.92 B	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Certara CERT	6.34 M	$ 7.19	1.93 %	$ 1.15 B	USA
Eton Pharmaceuticals ETON	1.06 M	$ 17.72	-2.37 %	$ 454 M	USA
Exelixis EXEL	-198 K	$ 40.99	-0.1 %	$ 11.1 B	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Galapagos NV GLPG	911 K	$ 33.13	-2.82 %	$ 2.69 B	Belgium
Capricor Therapeutics CAPR	399 K	$ 26.04	-3.07 %	$ 697 M	USA
Codexis CDXS	-10.4 M	$ 0.99	-2.92 %	$ 72.7 M	USA
Halozyme Therapeutics HALO	21.5 M	$ 69.39	-0.67 %	$ 8.32 B	USA
Harmony Biosciences Holdings HRMY	-680 K	$ 28.56	-1.19 %	$ 1.64 B	USA
ImmuCell Corporation ICCC	349 K	$ 6.3	-3.67 %	$ 51.5 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Immunic IMUX	5.02 M	$ 1.1	3.3 %	$ 171 M	USA
Immunovant IMVT	471 K	$ 26.99	-2.74 %	$ 4.09 B	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Inhibrx INBX	-580 K	$ 75.96	-1.97 %	$ 3.58 B	USA
InMed Pharmaceuticals INM	431 K	$ 0.75	-8.49 %	$ 1.84 M	Canada
INmune Bio INMB	2.28 M	$ 1.41	6.07 %	$ 25.4 M	USA
Insmed Incorporated INSM	83.8 M	$ 146.89	0.39 %	$ 29.2 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	1.26 M	$ 3.19	-4.49 %	$ 1.14 M	USA
Innate Pharma S.A. IPHA	566 K	$ 1.63	-1.21 %	$ 235 M	France
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	1.96 M	$ 29.11	-0.31 %	$ 1.69 B	USA